Establishment of gp100 and MART-1/Melan-A-specific cytotoxic T lymphocyte clones using in vitro immunization against preselected highly immunogenic melanoma cell clones

Cancer Immunology Immunotherapy

Volumn 48, Issue 5, 1999, Pages 239-246

  Kirkin, Alexei F ^a   Thor Straten, Per ^a   Hansen, Mia Riise ^a   Barfoed, Annette ^a   Dzhandzhugazyan, Karine N ^a   Zeuthen, Jesper ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

CTL clones; Melanoma cell clones; Melanoma associated antigens

Indexed keywords

DIFFERENTIATION ANTIGEN; GLYCOPROTEIN GP 100; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; MELAN A; MONOPHENOL MONOOXYGENASE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CELL ADHESION; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNOGENICITY; LYMPHOCYTE CLONE; MELANOMA CELL; MIXED LYMPHOCYTE CULTURE; PRIORITY JOURNAL;

ANTIGENS, NEOPLASM; CELL CULTURE TECHNIQUES; CLONE CELLS; COCULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HUMANS; MELANOMA; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; PEPTIDES; RECEPTORS, ANTIGEN, T-CELL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0032796832     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050571     Document Type: Article

References (29)

1. 1. Bakker ABH, Schreurs MWJ, de Boer AJ, Kawakami Y, Rosenberg SA, Adema GJ, Figdor CG (1994) Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 179:1005
2. 2. Bartkova J, Lukas J, Guldberg P, Alsner J, Kirkin AF, Zeuthen J, Bartek J (1996) The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res 56:5475
3. + cytotoxic T lymphocytes. J Exp Med 181:363
4. 4. Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159
5. + T cell help to elicit protective and therapeutic antitumor immunity. J Immunol 162:144
6. 6. Dzhandzhugazyan KN, Kirkin AF, thor Straten P, Zeuthen J (1998) Ecto-ATP diphosphohydrolase/CD39 is overexpressed in differentiated human melanomas. FEBS Lett 430:227
7. 7. Hérin M, Lemoine C, Weynants P, Vessière F, Van Pel A, Knuth A, Devos R, Boon T (1987) Production of stable cytolytic T-cell clones directed against autologous human melanoma. Int J Cancer 39:390
8. 8. Houghton AN, Davis LJ (1988) Phenotypic heterogeneity of melanoma. Prog Clin Biol Res 256:333-42:333
9. 9. Houghton AN, Eisinger M, Albino AP, Cairncross JG, Old LJ (1982) Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets. J Exp Med 156:1755
10. 10. Houghton AN, Real FX, Davis LJ, Cordon-Cardo C, Old LJ (1987) Phenotypic heterogeneity of melanoma. Relation to the differentiation program of melanoma cells. J Exp Med 165:812
11. + T cells in the antitumor immune response. J Exp Med 188:2357
12. 12. Kansas GS, Wood GS, Tedder TF (1991) Expression, distribution, and biochemistry of human CD39. Role in activation-associated homotypic adhesion of lymphocytes. J Immunol 146:2235
13. 13. Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR, Appella E, Rosenberg SA (1994) Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumour infiltrating lymphocytes. J Exp Med 180:347
14. 14. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA (1994) Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 91:6458
15. 15. Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, Robbins PF, Sette A, Appella E, Rosenberg SA (1995) Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 154:3961
16. 16. Kirkin AF, Petersen TR, Olsen AC, Li L, thor Straten P, Zeuthen J (1995) Generation of human-melanoma-specific T lymphocyte clones defining novel cytolytic targets with panels of newly established melanoma cell lines. Cancer Immunol Immunother 41:71
17. 17. Kirkin AF, thor Straten P, Zeuthen J (1996) Differential modulation by interferon gamma of the sensitivity of human melanoma cells to cytolytic T cell clones that recognize differentiation or progression antigens. Cancer Immunol Immunother 42:203
18. 18. Kirkin AF, Dzhandzhugazyan K, Zeuthen J (1998) The immunogenic properties of melanoma-associated antigens recognized by cytotoxic T lymphocytes. Exp Clin Immunogenet 15:19
19. 19. Kyburz D, Speiser DE, Aebischer T, Hengartner H, Zinkernagel RM (1993) Virus-specific cytotoxic T cell-mediated lysis of lymphocytes in vitro and in vivo. J Immunol 150:5051
20. 20. Marchand M, Weynants P, Rankin E, Arienti F, Belli F, Parmiani G, Cascinelli N, Bourlond A, Vanwijck R, Humblet Y, Canon JL, Laurent C, Naeyaert JM, Plagne R, Deraemaecker R, Knuth A, Jäger E, Brasseur F, Herman J, Coulie PG, Boon T (1995) Tumour regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 63:883
21. 21. Marchand M, Van Baren N, Weynants P, Brichard V, Dréno B, Tessier MH, Rankin E, Parmiani G, Arienti F, Humblet Y, Bourlond A, Vanwijck R, Liénard D, Beauduin M, Dietrich PY, Russo V, Kerger J, Masucci G, Jäger E, De Greve J, Atzpodien J, Brasseur F, Coulie PG, van der Bruggen P, Boon T (1999) Tumour regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 80:219
22. 22. Romero P, Gervois N, Schneider J, Escobar P, Valmori D, Pannetier C, Steinle A, Wölfel T, Liénard D, Brichard V, Van Pel A, Jotereau F, Cerottini JC (1997) Cytolytic T lymphocyte recognition of the immunodominant HLA-A *0201-restricted Melan-A/MART-1 antigenic peptide in melanoma. J Immunol 159:2366
23. 23. Schreurs MWJ, de Boer AJ, Figdor CG, Adema GJ (1998) Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection. Cancer Res 58:2509
24. 24. Stenholm ACO, Kirkin AF, Zeuthen J (1998) In vivo eradication of an established human melanoma by an in vitro generated autologous cytotoxic T cell clone: a SCID mouse model. Int J Cancer 77:476
25. 25. Suhrbier A, Burrows SR, Fernan A, Lavin MF, Baxter GD, Moss DJ (1993) Peptide epitope induced apoptosis of human cytotoxic T lymphocytes. Implications for peripheral T cell deletion and peptide vaccination. J Immunol 150:2169
26. 26. thor Straten P, Ralfkiaer E, Hendriks J, Seremet T, Vejlsgaard GL, Zeuthen J (1998) T-cell receptor variable region genes in cutaneous T-cell lymphomas. Br J Dermatol 138:3
27. 27. Toes REM, Offringa R, Blom RJ, Melief CJM, Kast WM (1996) Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc Natl Acad Sci USA 93:7855
28. 2+)-apyrase. J Biol Chem 271:9898
29. 29. Zarour H, De Smet C, Lehmann F, Marchand M, Lethé B, Romero P, Boon T, Renauld JC (1996) The majority of autologous cytolytic T-lymphocyte clones derived from peripheral blood lymphocytes of a melanoma patient recognize an antigenic peptide derived from gene Pme117/gp100. J Invest Dermatol 107:63